Gene therapy represents a transformative approach to treating Alzheimer's disease, with the potential to deliver disease-modifying payloads directly to the brain. AAIC 2026 features the latest advances in viral vector delivery, gene editing, and RNA-targeted approaches for neurodegenerative diseases["@sengupta2024"].
Key Topics
Viral Vector Delivery Systems
AAV Vectors
...
Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK
Overview
Mermaid diagram (expand to render)
Gene therapy represents a transformative approach to treating Alzheimer's disease, with the potential to deliver disease-modifying payloads directly to the brain. AAIC 2026 features the latest advances in viral vector delivery, gene editing, and RNA-targeted approaches for neurodegenerative diseases["@sengupta2024"].
Key Topics
Viral Vector Delivery Systems
AAV Vectors
Serotype selection: CNS-tropic AAV capsids
AAV9 and AAVrh.10: Most common in CNS applications
Novel capsids: Engineered variants with enhanced brain targeting
Delivery routes: Intrathecal, intravenous, and direct brain injection
Delivery Optimization
Blood-brain barrier crossing: Strategies to overcome BBB
Promoter selection: Cell-type specific expression
Dose optimization: Balancing efficacy and toxicity
[Sengupta R, et al., Gene therapy for Alzheimer's disease: Progress and challenges. Nat Rev Drug Discov. 2024 (2024)](https://doi.org/10.1038/s41573-024-00919-0)
[Hudry E, et al., AAV-mediated gene delivery to the brain. Nat Rev Neurosci. 2023 (2023)](https://doi.org/10.1038/s41583-023-00721-6)
[Kantor O, et al., RNA-targeted therapeutics for neurodegenerative disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00867-4)